Tuberculin Skin Test Disclosure and Consent Form

In compliance with CDC guidelines, the practice conducts a baseline two-step tuberculin skin test (TST) for all employees to help achieve its goal of providing a safe and healthful environment for its staff, patients, and visitors.

The baseline test is conducted as a means of early diagnosis of infection with M. tuberculosis. The tuberculin skin test is administered intradermally (Mantoux method) with 5tu of 0.1ml of PPD. The result of the test is measured quantitatively by the response to a specific dose. Adverse reactions in some highly sensitive individuals may include strong positive results, vesiculation, ulceration, or necrosis. Immediate erythematous reactions at the injection site may also occur for unknown reasons.

DO NOT rub, scratch or cover the test area with a band-aid. The area may be washed with soap and water then patted dry with a towel. Rubbing or scratching can cause irritation and the potential for a misinterpretation of the results. A physician or nurse must read the test between 48 to 72 hours after administration.

___ I have been given the opportunity to ask questions and consent to the administration of the two-step baseline tuberculin skin tests. I understand that a designated, trained HCW must read the results (test area) between 48 to 72 hours after each administration (with a 1-3 week interval between tests).

___ I have documentation of a previous positive skin test and do not require further tests. Instead, I have completed an annual symptom screen.

_____ _____
printed name date

_____
signature

Administration

Date/Time (first test): _____ Site: Right / Left forearm

Administered by: _____

Lot #: _____ Expiration Date: _____

Date/Time (second test): _____ Site: Right / Left forearm

Administered by: _____

Lot #: _____ Expiration Date: _____

Results

Date/Time Read: _____ Results: _____mm Negative / Positive

Read By: _____

Date/Time Read: _____ Results: _____mm Negative / Positive

Read By: _____

Form 601